Control Limitations in Models of T1DM and the Robustness of Optimal Insulin Delivery

Background: In insulin therapy, the blood glucose level is constrained from below by the hypoglycemic threshold, that is, the blood glucose level must remain above this threshold. It has been shown that this constraint fundamentally limits the ability to lower the maxima of the blood glucose level predicted by many mathematical models of glucose metabolism. However, it is desirable to minimize hyperglycemia as well. Hence, a desirable insulin input is one that minimizes the maximum glucose concentration while causing it to remain above the hypoglycemic, or higher, threshold. It has been shown that this input, which we call optimal, is characterized by glucose profiles for which either each maximum of the glucose concentration is followed by a minimum or each minimum is followed by a maximum. Methods: We discuss the implication of this inherent control limitation for clinical practice and test, through simulation, the robustness of the optimal input to a number of different model and parameter uncertainties. We further develop guidelines on how to design an optimal insulin input that is robust to such uncertainties. Results: The optimal input is in general not robust to uncertainties. However, a number of strategies may be used to ensure the blood glucose level remains above the hypoglycemic threshold and the maximum blood glucose level achieved is less than that achieved by standard therapy. Conclusions: An understanding of the limitations on the controllability of the blood glucose level is important for future treatment improvements and the development of artificial pancreas systems.

[1]  C. Cobelli,et al.  The UVA/PADOVA Type 1 Diabetes Simulator , 2014, Journal of diabetes science and technology.

[3]  Graham C. Goodwin,et al.  A fundamental control limitation for linear positive systems with application to Type 1 diabetes treatment , 2015, Autom..

[4]  R. Bergman Minimal Model: Perspective from 2005 , 2006, Hormone Research in Paediatrics.

[5]  Maria M. Seron,et al.  Optimality of Unconstrained Pulse Inputs to the Bergman Minimal Model , 2018, IEEE Control Systems Letters.

[6]  P. Vicini,et al.  Pharmacokinetic and Pharmacodynamic Properties of Insulin Aspart and Human Insulin , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[7]  Garry M. Steil,et al.  Identification of Intraday Metabolic Profiles during Closed-Loop Glucose Control in Individuals with Type 1 Diabetes , 2009, Journal of diabetes science and technology.

[8]  R. Hovorka,et al.  Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. , 2004, Physiological measurement.

[9]  G. Steil,et al.  Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era , 2015, Diabetes Care.

[10]  Yang Kuang,et al.  Mathematical models and software tools for the glucose-insulin regulatory system and diabetes: an overview , 2006 .

[11]  Pier Giorgio Fabietti,et al.  Control oriented model of insulin and glucose dynamics in type 1 diabetics , 2006, Medical and Biological Engineering and Computing.

[12]  R. Hovorka,et al.  Simulation models for in silico testing of closed-loop glucose controllers in type 1 diabetes , 2008 .

[13]  Robert S Parker,et al.  Dynamic modeling of free fatty acid, glucose, and insulin: an extended "minimal model". , 2006, Diabetes technology & therapeutics.

[14]  F. Doyle,et al.  Quest for the Artificial Pancreas: Combining Technology with Treatment , 2010, IEEE Engineering in Medicine and Biology Magazine.

[15]  R. Parker,et al.  Dynamic Modeling of Exercise Effects on Plasma Glucose and Insulin Levels , 2007, Journal of diabetes science and technology.

[16]  Patricio Colmegna,et al.  Analysis of three T1DM simulation models for evaluating robust closed-loop controllers , 2014, Comput. Methods Programs Biomed..